Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

Benzer Materyaller

• Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
  Yazar:: Zhang, Shannon S, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
  Yazar:: Vasconcelos, Pedro E.N.S., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• EGFR exon 20 insertion mutations display sensitivity to Hsp90 inhibition in preclinical models and lung adenocarcinomas
  Yazar:: Jorge, Susan E., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Patterns of Treatment and Real‐World Outcomes of Patients With Non‐small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
  Yazar:: Geoffrey Liu, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-02-01)
• Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity
  Yazar:: Xiuning Le, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-09-01)